chiauranib

multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRalpha, and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R

Also Known As:

Networked: 9 relevant articles (1 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Deng, Manman: 3 articles (01/2021 - 01/2018)
2.	Fang, Zhihong: 3 articles (01/2021 - 01/2018)
3.	Shi, Yuanfei: 3 articles (01/2021 - 01/2018)
4.	Xu, Bing: 3 articles (01/2021 - 01/2018)
5.	Yu, Lian: 2 articles (01/2021 - 06/2019)
6.	Ning, Zhiqiang: 2 articles (10/2019 - 01/2019)
7.	Shan, Song: 2 articles (10/2019 - 03/2017)
8.	Zhou, You: 2 articles (10/2019 - 03/2017)
9.	Zhao, Haijun: 2 articles (06/2019 - 01/2018)
10.	Zhao, Jintao: 2 articles (06/2019 - 01/2018)

Related Diseases

1.	Lymphoma (Lymphomas) 01/01/2018 - "CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in vitro and in vivo." 01/01/2019 - "This phase I dose-escalation study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor activity of chiauranib in patients with refractory advanced solid tumor and lymphoma. " 01/01/2021 - "In this study, we investigated the preclinical anti-lymphoma efficacies and potential mechanism of action of a novel treatment approach, combining the BCL2 inhibitor venetoclax with CS2164, a new orally active multitarget inhibitor, in HGBL-DHL models. "
2.	Neoplasms (Cancer) 03/01/2017 - "The in vivo animal efficacy studies revealed that CS2164 induced remarkable regression or complete inhibition of tumor growth at well-tolerated oral doses in several human tumor xenograft models. " 10/01/2019 - "However, the ability of CS2164 to modulate antitumor immunity in an immune-competent mouse tumor model remains undefined, although antiangiogenic treatment has been reported to affect immune cell infiltration and remodel the tumor immune microenvironment. " 10/01/2019 - "As a novel orally active multitarget small molecule inhibitor, CS2164 has shown broad antitumor activities against several human tumor xenograft models in immune-compromised mice. " 03/01/2017 - "CS2164 also showed induction of G2/M cell cycle arrest and suppression of cell proliferation in tumor tissues through the inhibition of Aurora B-mediated H3 phosphorylation. " 12/22/2022 - "In conclusion, chiauranib may be a potential therapy to treat t-FL, since it inhibits tumor growth and migration and induces apoptosis by altering the VEGFR2/ERK/STAT3 signaling pathway."
3.	Inflammation (Inflammations) 01/01/2019 - "Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors." 03/01/2017 - "CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency." 03/01/2017 - "Collectively, these results indicate that CS2164 is a highly selective multi-kinase inhibitor with potent anti-tumor activities against tumor angiogenesis, mitosis and chronic inflammation, which may provide the rationale for further clinical assessment of CS2164 as a therapeutic agent in the treatment of cancer." 01/01/2019 - "Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRα, and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R. " 03/01/2017 - "CS2164 inhibited the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B and chronic inflammation-related kinase CSF-1R in a high potency manner with the IC50 at a single-digit nanomolar range. "
4.	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/22/2022 - "Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway."
5.	Leukemia 06/15/2019 - "In conclusion, our study indicates that CS2164 exerts anti-leukemia effect by inducing apoptosis through suppressing the VEGFR2 pathway, supporting a potential role for CS2164 in the treatment of AML."

Related Drugs and Biologics

1.	venetoclax
2.	Aurora Kinase B
3.	Phosphotransferases (Kinase)
4.	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)
5.	Cytokines
6.	Proteins (Proteins, Gene)
7.	Ligands
8.	Asparaginase (Elspar)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy